secwatch / observer
8-K filed September 2, 2025, 7:59 PM ET ticker CNTX CIK 0001842952
regulatory confidence high sentiment negative materiality 0.60

Context Therapeutics Inc. (CNTX): Nasdaq/NYSE listing notice — Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance

Context Therapeutics Inc.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Context Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange
nasdaq
Notice
extension granted
Deficiency
minimum bid price
Rules
5550(a)(2)
Exact text from the filing
August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the “Extension Deadline”), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that
View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR
accession 0001842952-25-000085
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.